RxDoctor Payments Data

Kimberly Connally, PA

Physician Assistant · Columbus, GANPI 1487856092

Payments from drug & device makers

$12,569in general payments, 2019–2025

Across 414 payments — averaging $30.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$4K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Novartis$1K
  • Amgen$1K
  • AbbVie$980
  • Lilly USA, LLC$470
  • plus $4K from 21 others

What the payments were for

  • Consulting fees$2,82923%
  • Food & beverage$9,21573%
  • Education$5254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,569 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$280,071
Medicare patients
890
Services billed
5,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast55$352,013
Dupixent SyringeDupilumab72$265,632
Cosentyx Unoready PenSecukinumab24$241,042
Humira(Cf) PenAdalimumab18$224,638
Dupixent PenDupilumab45$178,697
TremfyaGuselkumab13$176,110
Taltz AutoinjectorIxekizumab13$82,532
AdbryTralokinumab-Ldrm19$71,191
OpzeluraRuxolitinib Phosphate15$30,293
Clobetasol Propionate212$9,975
Tacrolimus23$4,129
Ketoconazole190$4,026
Fluorouracil62$3,425
Triamcinolone Acetonide191$2,625
Doxycycline Hyclate119$2,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,158$352,01355 claims
Johnson & JohnsonTremfya$426$176,11013 claims
LEO Pharma Inc.Adbry$95$71,19119 claims
Incyte CorporationOpzelura$326$30,29315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →